Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGT-309 in lung cancer surgery
NCT06145048Phase 2Completed
- Sponsor
- Vergent Bioscience
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of abenacianine in lung cancer, lung metastases (LM), sponsored by Vergent Bioscience. Started Oct 2023; status: completed.
02
Drugs
abenacianine
03
Conditions
lung cancerlung metastases (LM)
Beyond the preview
Go deeper on NCT06145048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06145048.